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ABSTRACT 
Toxoplasma gondii (T. gondii) is an obligate intracellular parasite with worldwide distribution. 
It is estimated that near one-third of the people around the globe are latently seropositive for 
the parasite. Since the current common drugs are incapable in the elimination of parasites within 
tissue cysts, the development of an effective vaccine has high priority for researchers to limit 
the infection. During recent years, non-stop efforts of scientists have made great progress in the 
identification and development of T. gondii candidate vaccines. However, there is a lack of a 
commercially licensed vaccine for human application yet. Rhomboid proteases (ROMs) are a 
class of serine proteases that have an important role in the invasion of the parasites that can be 
considered as a new target for vaccine strategy. They also play critical roles in mitochondrial 
fusion and growth factor signaling, allowing the parasite to completely enter into the host cell. 
In the current review, we have summarized the recent progress regarding the development of 
ROM-based vaccines against acute and chronic T. gondii infection in animal models. 
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INTRODUCTION 
Toxoplasma gondii (T. gondii) is an obli-
gate intracellular protozoan with cosmopoli-
tan distribution in five continents (Foroutan-
Rad et al., 2016; Wang et al., 2017) which can 
infect several warm-blooded vertebrates such 
as rodents, birds, marine mammals, domes-
tic/wild mammals, etc. (Dubey, 2008; 
Khademvatan et al., 2017; Rostami et al., 
2017). Moreover, T. gondii has been isolated 
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from Iranian snakes (Nasiri et al., 2016). It is 
estimated that more than one-third of the hu-
man population are latently infected with the 
parasite in different groups throughout the 
globe (Foroutan-Rad et al., 2016; Wang et al., 
2017). In general, toxoplasmosis is oftentimes 
asymptomatic among immunocompetent sub-
jects, whereas in organ transplant recipients, 
HIV-positive persons, individuals with malig-
nancy, and newborns can cause severe com-
plications and life-threatening outcomes 
(Fallahi et al., 2018; Gharavi et al., 2011; 
Soltani et al., 2018; Wang et al., 2017). 
More recently, based on systematic re-
view and meta-analysis papers from a global 
perspective, the positive association between 
toxoplasmosis with some diseases (type 2 di-
abetes mellitus: odds ratio [OR]: 2.39; P = 
0.013) and psychiatric disorders such as bipo-
lar disorder (OR: 1.52; P = 0.02), obsessive–
compulsive disorder (OR: 3.4; P < 0.001), and 
schizophrenia (OR: 1.81; P < 0.00001) have 
been documented (Majidiani et al., 2016; 
Sutterland et al., 2015). 
The commonly prescribed drugs for the 
treatment of T. gondii infection only can limit 
the multiplication of tachyzoites in the initial 
phase of infection, while they are unable to 
eliminate the encysted parasites within tissue 
cysts (Antczak et al., 2016). Accordingly, the 
development of an effective vaccine has high 
priority for investigators to limit the infection 
in animals and humans. During the three past 
decades, non-stop efforts of researchers have 
made great achievements in the identification 
and development of T. gondii candidate vac-
cines mainly on rhoptry proteins (ROPs), sur-
face antigens (SAGs), microneme proteins 
(MICs), dense granule antigens (GRAs), cal-
cium-dependent protein kinases (CDPKs), 
and some other antigens (Foroutan and 
Ghaffarifar, 2018; Foroutan et al., 2018b, 
2019; Kur et al., 2009; Zhang et al., 2015a). 
In the past several years, the different vac-
cine types with various strategies have been 
developed experimentally throughout the 
globe that ranged from killed vaccines, live or 
attenuated vaccines, recombinant subunit pro-
teins, live vectors to DNA vaccines or multi-
epitope-based vaccines (Foroutan and 
Ghaffarifar, 2018; Foroutan et al., 2019; 
Ghaffarifar, 2015, 2018; Kur et al., 2009; 
Zhang et al., 2015a). These vaccines with var-
ious vaccination routes in different mouse 
models have verified partial protection and re-
duction of brain cysts burden after challenge 
with avirulent and/or virulent Toxoplasma 
strains (Foroutan and Ghaffarifar, 2018; 
Foroutan et al., 2018b; Han et al., 2017; Kur 
et al., 2009; Li et al., 2012; Zhang et al., 
2015a; Zhang et al., 2015b). However, cur-
rently there is a lack of an approved commer-
cial vaccine for human use (Zhang et al., 
2015a). 
 
RHOMBOID PROTEASES (ROMS) 
In apicomplexan protozoa, including Tox-
oplasma and Plasmodium, a number of spe-
cific molecules are required for entering into 
cells or invasion procedure (Dowse et al., 
2008). Rhomboid proteases are a class of ser-
ine proteases that have an important role in 
the invasion of the parasites (Kim, 2004). In-
vasion by T. gondii and generally all apicom-
plexan parasites is carried out by adhesion re-
ceptors. Rhomboid proteases are thought to 
cleave adhesins within their transmembrane 
segments, thus allowing the parasite to disen-
gage from receptors and completely enter the 
host cell (Shen et al., 2014). ROM antigens 
are conserved molecules in T. gondii which 
recently become attractive as a target in vac-
cine based purposes (Dowse et al., 2005; Li et 
al., 2012). These ubiquitous serine proteases 
are able to recognize and cleave their sub-
strates within their transmembrane domains. 
Recent data strongly suggest that parasite-de-
rived, rhomboid like proteases cleave MIC 
proteins in order to release them from the par-
asite membrane (Brossier et al., 2008). They 
also play critical roles in mitochondrial fu-
sion, growth factor signaling, and invasion 
procedure (Li et al., 2012).  
In Plasmodium spp, they have been 
named PfROM1, PfROM3, PfROM4 and 
PfROM6 (Kim, 2004). In Theileria annulata 
and T. parva, only ROM4 and ROM6 have 
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been found (Dowse and Soldati, 2005). The 
nomenclature is carried out using the first let-
ters of the genus and species and using ROM 
and the number of each rhomboid. Every 
number shows the order of its detection 
(Dowse and Soldati, 2005). For the first time, 
ROMs have been identified in Drosophila 
melanogaster, where they have a signaling 
role (Brossier et al., 2008), it also has a cleav-
ing role (Brossier et al., 2005). T. gondii pos-
sesses six ROMs namely TgROM1-TgROM6 
which are expressed in different stages of the 
life cycle (Dowse et al., 2005). For instance, 
TgROM1 is localized to the micronemes and 
Golgi and participates in the invasion process. 
Since the position of ROM1 is in the micro-
nemes, so ROM1 only acts during invasion 
(Dowse et al., 2008). TgROM2 and TgROM3 
are localized to the Golgi and mainly are ex-
pressed in sporozoites (Brossier et al., 2008; 
Dowse et al., 2008; Shen et al., 2014). 
TgROM4 exits in plasma membrane (Shen et 
al., 2014), and is expressed mainly in tachyzo-
ites, and to a less extent in bradyzoites and 
sporozoites (Han et al., 2017). ROM4 is an 
activator for the micronemes and micronemes 
activity depends on ROM4. Also, ROM4 
counts as the first molecule in invasion 
(Rahimi et al., 2017; Shen et al., 2014). 
TgROM4 is the central molecule in regulating 
MIC2, MIC3, and MIC6 and helps the para-
site to enter into cells (Han et al., 2017). 
TgROM5 localizes to the surface at the poste-
rior end and is the functioning ROM against a 
wide number of substrates unlike other ROMs 
(Kim, 2004). 
In a study, Brossier et al. investigated the 
role of microneme rhomboid protease 
TgROM1 during in vitro growth of T. gondii. 
The results showed that suppression of 
TgROM1 using the tetracycline-regulatable 
system caused a modest decrease in invasion 
role of TgROM1 and also ROM1 is essential 
for appropriate intracellular growth of T. 
gondii (Brossier et al., 2008). Also, in 2010 
Buguliskis et al. investigated the role of 
TgROM4 using a knockout technique, the re-
sults showed that suppression of TgROM4 led 
to interruption of normal gliding and cell mo-
tility and finally invasion process. Therefore, 
TgROM4 is critical for efficient cell motility 
and invasion of host cells by T. gondii 
(Buguliskis et al., 2010). Furthermore, Shen 
et al. (2014) carried out a single, double, and 
triple knockout for the three ROMs expressed 
in T. gondii tachyzoites to demonstrate the ex-
act roles of each ROM during the invasion. 
The results revealed that ROM4 acts first in 
adhesin processing and host cell invasion, 
whereas ROM1 or ROM5 do not have a 
prominent role in the invasion (Shen et al., 
2014). The specific features and main func-
tions of some ROMs have been inserted in Ta-
ble 1. 
 
DNA VACCINES 
The DNA vaccination as a novel strategy 
has a critical role against acute and chronic T. 
gondii infection; it has very strong immuno-
genicity and can induce both humoral and cel-
lular immunity in the body as well as stimu-
lates dendritic cells (DCs) to be matured and 
makes them strong stimulators of T-cell im-
munity. Therefore, in studies of vaccines 
against T. gondii infection, the DNA vaccina-
tion has received much attention (Foroutan et 
al., 2019; Kur et al., 2009; Li and Petrovsky, 
2016; Zhang et al., 2015a). Some advantages 
of DNA vaccines compared with traditional 
vaccines are as follows: unique design, versa-
tility, safety, ease of production, ease of han-
dling, absence of any type of microorganism, 
etc. (Foroutan and Ghaffarifar, 2018; Li and 
Petrovsky, 2016). Accumulating evidence has 
been shown that successful DNA immuniza-
tion tends to stimulate Th1-type rather than 
Th2-type immune response (Li and 
Petrovsky, 2016). There are different ways of 
administering a DNA vaccine to the body, in-
cluding syringe injection (intramuscular, sub-
cutaneous, mucosal), gene gun immunization, 
nanoparticles, liposomes, oral delivery path-
way or nasal spray (Doria-Rose and 
Haigwood, 2003; Li and Petrovsky, 2016). In 
general,  direct  injection  of  naked  plasmid 
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Table 1: The main features and functions of some ROMs 
Anti-
gens 
Features or major effect on host References 
ROM1 ROM1 is essential for invasion of host cells and played an important role in parasite growth in vitro. 
ROM1 was localized in the secretory pathway of the parasite, including the Golgi apparatus and micro-
nemes, which contained adhesive proteins involved in invasion of host cells. 
Knockdown of TgROM1 resulted in a mild growth defect. 
ROM1 is expressed in the tachyzoite stage. 
Brossier et al., 2005;  
Brossier et al., 2008;  
Dowse and Soldati, 2004;  
Dowse et al., 2008;  
Kim, 2004;  
Li et al., 2012;  
Shen et al., 2014 
ROM2 ROM2 is mainly expressed in the sporozoites, with much lower expression in tachyzoites. 
ROM2 is able to cleave chimeric proteins composed of the transmembrane domain of microneme protein 2 
(MIC2) or MIC12. 
Brossier et al., 2005; 
Dowse et al., 2005 
ROM3 ROM3 is mainly expressed in the sporozoites, with much lower expression in tachyzoites. Brossier et al., 2005 
ROM4 ROM4 is expressed primarily in tachyzoites, at lower levels in bradyzoites, and is weakly detected in sporo-
zoites. 
ROM4 is localized to the plasma membrane of T. gondii and uniformly distributed on the parasite surface. 
ROM4 plays an important role in regulating MIC2, MIC3, MIC6, and apical membrane antigen 1 (AMA1). 
ROM4 participates in processing of surface adhesins, including MIC2, AMA1 and MIC3, which is important 
for the motility and invasion of T. gondii. 
ROM4 is the primary protease involved in adhesin processing and host cell invasion. 
ROM4 deletion leads to partial impairment in host-cell invasion. 
Suppression of ROM4 partially impairs lytic growth without affecting intracellular replication. 
Suppression of ROM4 reduces the frequency of moving junction formation. 
Suppression of ROM4 resulted in disruption of normal gliding, with the majority of parasites twirling on their 
posterior ends. 
Brossier et al., 2005; 
Buguliskis et al., 2010;  
Dowse et al., 2005;  
Han et al., 2017;  
Rugarabamu et al., 2015;  
Shen et al., 2014;  
Zhang et al., 2015b 
ROM5 ROM5 localizes to the surface and accumulates at the posterior end of the parasite membrane. 
ROM5 can cleave the transmembrane domains of TgMIC2, TgMIC6 and TgMIC12 and the protease re-local-
izes to the posterior pole of the parasite after stimulation of MIC secretion, suggesting that TgROM5 is es-
sential for T. gondii invasion. 
ROM5 is dispensable for parasite survival. 
Brossier et al., 2005;  
Rugarabamu et al., 2015;  
Zhang et al., 2015b 
ROM6 ROM6 is localized in the mitochondria. Dowse and Soldati, 2005 
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DNA enters to the cell cytoplasm which can 
express encoded proteins, thereby enhancing 
specific humoral and cell-mediated immune 
responses (Li and Petrovsky, 2016). Despite 
the advances in DNA vaccine technology, 
there are various limitations associated with 
the use of DNA vaccines, which occasionally 
confined the immunogenicity of them such as 
dosages of inoculum, the delivery route, and 
also inadequate ability to produce non-protein 
antigens (Foroutan and Ghaffarifar, 2018; Li 
and Petrovsky, 2016). In order to provide suf-
ficient protection and prevent from the attach-
ment of T. gondii to related host cell recep-
tors, B-cell activation and antibody produc-
tion are needed. In this regard, Immunoglobu-
lin G (IgG) as an essential antibody can elim-
inate the parasite via activation of the classi-
cal complement cascade as well as enhance-
ment of killing activity of macrophages 
(MQs) (Sayles et al., 2000). Furthermore, the 
production of nitric oxide (NO) from acti-
vated MQs is able to control T. gondii repli-
cation (Cabral et al., 2018). 
Various studies have shown that protec-
tion against T. gondii infection is developed 
through both humoral and cellular immune re-
sponses as well as regulatory cytokines. Gen-
erally, secretion of interferon-γ (IFN-γ) from 
CD4+ and CD8+ T cells to be effective at con-
trolling and limiting parasite growth. Also, 
this signature cytokine could inhibit reactiva-
tion of intracellular bradyzoites during the 
chronic phase of infection (Denkers and 
Gazzinelli, 1998; Suzuki et al., 1988). In ad-
dition, interleukin 2 (IL-2) and IL-12 secreted 
through Th1 type cells can promote host re-
sistance against T. gondii infection, whereas 
type 2 cytokines such as IL-4, IL-5, IL-9, IL-
10, and IL-13 regulates Th2 responses 
(Mosmann and Moore, 1991; Zhang et al., 
2015a). The studies have shown that good 
DNA vaccines stimulate major histocompati-
bility complex (MHC) class I and II mole-
cules that lead to the activation of CD8+ and 
CD4+ T-cell immune responses against this op-
portunistic agent (Li and Petrovsky, 2016; 
Tighe et al., 1998).  
Recently, it was shown that DNA vac-
cination with ROM1, ROM4 and ROM5 has 
become popular and can promote an appropri-
ate immune response against T. gondii infec-
tion (Han et al., 2017; Li et al., 2012; Rahimi 
et al., 2017; Zhang et al., 2015b). In fact, cal-
cium phosphate nanoparticles (CaPNs) are 
considered as adjuvants or delivery vehicles 
that extend the antigen releasing period to 
evoke strong and long-lasting immune re-
sponses with increasing the uptake of antigen 
by antigen presenting cells (APCs) (Gregory 
et al., 2013). In this context, Rahimi et al. 
(2017) designed an experimental study to 
evaluate the protective efficacy of ROM4 
alone or with coated CaPNs as the adjuvant in 
BALB/c mice. They reported that co-admin-
istration of CaPNs with pcROM4 increases 
the survival time of the vaccinated groups (P 
< 0.05) than those mice in control groups 
when challenged with 1×103 tachyzoites of 
RH strain. Furthermore, a mixed Th1/Th2 re-
sponse with the predominance of IgG2a over 
IgG1 (P < 0.05), and high secretion of IFN-γ 
(P < 0.05) were observed as the outcome of 
immunization, compared with control groups. 
This data suggests that immunization with 
nanoadjuvant of CaPNs as a novel adjuvant 
for DNA vaccine could elicit a strong specific 
immune response (Rahimi et al., 2017). In an-
other study, Zhang et al. (2015b) designed a 
comprehensive study on ROM4 and ROM5 
proteins against acute and chronic T. gondii 
infection in Kunming mice. The mice immun-
ized with pVAX-TgROM5 or pVAX-
TgROM4 revealed higher levels of some cy-
tokines, as well as increased the level of IgG 
antibody titers (the predominance of IgG2a 
production). Notably, the percentage of CD4+ 
and CD8+ T cells were enhanced (P < 0.001). 
Besides, the number of brain cysts were sig-
nificantly reduced (72.04 % for pVAX-
TgROM5 and 44.08 % for pVAX-TgROM4, 
respectively) and increased survival rate 
(20 % and 13.3 %, 35 days post challenge in 
mice immunized with pVAX-TgROM5 and 
pVAX-TgROM4, respectively) compared 
with control groups (death within 8 days, P < 
0.05). These results indicated that pVAX-
EXCLI Journal 2019;18:259-272 – ISSN 1611-2156 
Received: December 11, 2018, accepted: April 17, 2019, published: May 21, 2019 
 
 
264 
TgROM5 is to be more effective than pVAX-
TgROM4 that can enhance the protective im-
munity against acute and chronic T. gondii in-
fection (Zhang et al., 2015b). TgROM1 com-
posed of adhesive proteins that is located in 
the secretory pathway of the parasite. It is 
well known that it is essential for parasite 
growth in vitro as well as expressed in the 
tachyzoite stage of T. gondii (Brossier et al., 
2008). Li et al. (2012) evaluated the protec-
tive efficacy of TgROM1. The findings 
showed that pVAX-ROM1 is able to induce 
the high production of IFN-γ, IL-2, IL-4, and 
IL-10 significantly compared with those 
groups that injected pVAX1 alone or PBS (P 
< 0.05). Moreover, higher percentages of T-
CD4+ cells (P < 0.05) and higher levels of IgG 
antibodies than control (P < 0.05) were rec-
orded. Also, pVAX-ROM1 immunization, 
leads to higher survival time (12.5 ± 0.7 days, 
P < 0.05) than those mice in control groups. 
The authors suggested that TgROM1 could be 
considered as a promising vaccine candidate 
against T. gondii infection (Li et al., 2012). 
More details of immunization experiments 
with DNA vaccines against T. gondii infec-
tion are listed in Table 2. 
 
ROM PEPTIDE VACCINE 
In recent decade, bioinformatics as a new-
found interdisciplinary science has become 
popular among scientists which analyze the 
biological data by recruiting the defined tech-
nologies and algorithms from statistics, phys-
ics, computer sciences, mathematics, medi-
cine, and biology (Romano et al., 2011). This 
novel science can be used for several pur-
poses, including predicting protein structures, 
biological characteristics, functions, epitopes, 
design of new vaccines, etc. It is worth to 
mention that bioinformatics techniques had 
satisfactory precision and accuracy and 
needed low time (Foroutan et al., 2018a; 
Khademvatan et al., 2013; Romano et al., 
2011; Wang et al., 2016). The prediction of 
potent epitopes is necessary to evaluate the 
immunogenicity of target antigen for design 
of reverse vaccines. Hence, bioinformatics 
tools and online servers surely assist research-
ers to predict and identify the potential B and 
T cell epitopes (Foroutan et al., 2018a; Wang 
et al., 2016). 
In this context, Han et al. (2017) con-
ducted a comprehensive study. In brief, the 
antigenic features of ROM4 and SAG1 were 
analyzed and then compared together by em-
ploying bioinformatics tools. The DNASTAR 
outputs revealed that ROM4 had a better anti-
genic index, surface probability, and flexibil-
ity than SAG1 molecule. Moreover, the IC50 
values of HLA-DRB1*01:01, H2-IAb, H2-
IAd, and H2-IEd alleles of ROM4 were 
smaller than those of SAG1, indicating that 
ROM4 may have better Th epitopes than 
SAG1. The authors identified a polypeptide 
(YALLGALIPYCVEYWKSIPR) using bio-
informatics methods and then were tested in 
BALB/c mice. After immunization, increased 
levels of IgG antibody response were ob-
served. Also, in subsets of IgG, the predomi-
nance of IgG2a over IgG1 was recorded. In 
those mice that vaccinated with ROM4 pep-
tide, the production of IFN-γ, IL-2, and IL-12 
were significantly increased, compared with 
control groups. Also, increased survival time 
(P < 0.05) and reduction of brain cysts load 
(P < 0.05) were seen, compared with control 
groups (Table 2). The authors remarked that 
this vaccine could be considered as a potent 
promising vaccine candidate against chronic 
and acute T. gondii infection (Han et al., 
2017). 
 
PRIME-BOOST STRATEGIES 
Traditional vaccines such as live attenu-
ated micro-organisms and inactivated micro-
organisms are used in medical purposes 
widely, but these vaccines are not any more 
appropriate choices because of several rea-
sons, including lack of adequate efficiency, 
etc. (Lee and Nguyen, 2015). As evident, sub-
unit vaccines are based on peptides, proteins 
or polysaccharides containing protective anti-
gens. However, the recombinant subunit vac-
cines are  poorly  immunogenic  and  to solve 
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Table 2: Baseline characteristics of included studies 
Antigens Adju-
vant or  
carrier 
Ag  
deliv-
ery 
Mouse 
strain 
Challenge Immune responses Brain cyst 
load 
Survival Refer-
ences 
ROM1 - Plas-
mid, 
i.m 
BALB/c 1 × 103 
tachyzoites, 
RH strain, i.p 
Induced a strong IgG antibody re-
sponse (P < 0.05) 
 
↑ proliferation SI (1.22 ± 0.05, P < 
0.05) 
 
↑ IFN-γ (454.56 pg/ml, P < 0.05), 
IL-2 (383.45 pg/ml, P < 0.05), IL-4 
(239.64 pg/ml, P < 0.05) and IL-10 
(422.89 pg/ml, P < 0.05) 
 
↑ percentages of CD4+ T cells (P < 
0.05) 
 
No significant difference in the 
percentages of CD8+ lymphocytes 
was observed among different 
groups. 
Not re-
ported 
Increased survival time 
(12.5 ± 0.7 days, P < 
0.05) 
 
Control mice were died 
within 5 days. 
Li et al., 
2012 
ROM4 - Plas-
mid, 
i.m 
Kun-
ming 
Acute: 1 × 103 
tachyzoites, 
RH strain, i.p 
 
Chronic: 10 tis-
sue cysts PRU 
strain, orally 
Induced a strong IgG antibody re-
sponse (P < 0.001) 
 
Induced mixed Th1/Th2 immune 
responses with the predominance 
of IgG2a over IgG1 
 
↑ splenocyte proliferation (P < 
0.01) 
 
↑ percentages of CD4+ and CD8+ 
cells (P < 0.001) 
 
↑ IL-2 (P < 0.01) 
 
Reduced 
(44.08 %, 
P < 0.001) 
Increased survival rate 
(13.3 %, 35 days post 
challenge) 
 
Control mice were died 
within 8 days. 
 
Zhang et 
al., 
2015b 
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Antigens Adju-
vant or  
carrier 
Ag  
deliv-
ery 
Mouse 
strain 
Challenge Immune responses Brain cyst 
load 
Survival Refer-
ences 
Similar levels of IFN-γ, IL-12 
(p70), IL-4, IL-23, and IL-10 be-
tween mice vaccinated with pVAX-
TgROM4 and control groups (P > 
0.05) 
ROM4 CaPNs Plas-
mid, 
i.m 
BALB/c 1 × 103 
tachyzoites, 
RH strain, i.p 
Induced a strong IgG antibody re-
sponse (P < 0.05) 
 
Induced mixed Th1/Th2 immune 
responses with predominance of 
IgG2a over IgG1 
 
↑ splenocyte proliferation (P < 
0.05) 
 
↑ IFN-γ (P < 0.05) 
 
Similar levels of  IL-4 between im-
munized mice and control groups 
(P > 0.05) 
Not re-
ported 
Increased survival time 
(P < 0.05) 
 
pcROM4: death within 
12 days (P < 0.05) 
 
pcROM4-CaPNs: death 
within 13 days (P < 
0.05) 
 
Control mice died 
within 6 days 
Rahimi et 
al., 2017 
ROM4 - Plas-
mid, 
i.m 
BALB/c Acute: 1 × 104 
tachyzoites, 
RH strain, i.p 
 
Chronic: 20 tis-
sue cysts PRU 
strain, orally 
Induced a strong IgG antibody re-
sponse (P < 0.05) 
 
The predominance of IgG2a over 
IgG1 
 
↑ IFN-γ (531.8 ± 63.3 pg/ml, P < 
0.05), IL-2 (212.4 ± 22.4 pg/ml, P 
< 0.05), IL-12 (p70) (146.1 ± 31.1 
pg/ml, P < 0.05) 
 
Similar levels of  IL-4 and IL-10 
between immunized mice and 
control groups (P > 0.05) 
Reduced 
(P < 0.05) 
Prolonged survival time 
(12 days compared 
with 6 days in control, P 
< 0.05) 
Han et 
al., 2017 
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Antigens Adju-
vant or  
carrier 
Ag  
deliv-
ery 
Mouse 
strain 
Challenge Immune responses Brain cyst 
load 
Survival Refer-
ences 
ROM4 - Pep-
tide, 
i.m 
BALB/c Acute: 1 × 104 
tachyzoites, 
RH strain, i.p 
 
Chronic: 20 tis-
sue cysts PRU 
strain, orally 
Induced a strong IgG antibody re-
sponse (P < 0.05) 
 
The predominance of IgG2a over 
IgG1 
 
↑ IFN-γ (488.6 ± 79.1 pg/ml, P < 
0.05), IL-2 (210.1 ± 20.7 pg/ml, P 
< 0.05), IL-12(p70) (132.9 ± 26.0 
pg/ml, P < 0.05) 
 
Similar levels of  IL-4 and IL-10 
between immunized mice and 
control groups (P > 0.05) 
Reduced 
(P < 0.05) 
Prolonged survival time 
(11 days compared 
with 6 days in control, P 
< 0.05) 
Han et 
al., 2017 
ROM5 - Plas-
mid, 
i.m 
Kun-
ming 
Acute: 1 × 103 
tachyzoites, 
RH strain, i.p 
 
Chronic: 10 tis-
sue cysts PRU 
strain, orally 
Induced a strong IgG antibody re-
sponse (P < 0.001) 
 
Induced mixed Th1/Th2 immune 
responses with the predominance 
of IgG2a over IgG1 
 
↑ splenocyte proliferation (P < 
0.001) 
 
↑ percentages of CD4+ and CD8+ 
cells (P < 0.001) 
 
↑ IFN-γ (P < 0.001) , IL-2 (P < 
0.001), and IL-12 (p70) (P < 0.05) 
 
Similar levels of IL-4, IL-23, and 
IL-10 between mice vaccinated 
with pVAX-TgROM5 and control 
groups (P > 0.05)  
Reduced 
(72.04 %, 
P < 0.001) 
Increased survival rate 
(20 %, 35 days post 
challenge, P < 0.05) 
 
Control mice died 
within 8 days. 
 
Zhang et 
al., 
2015b 
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Antigens Adju-
vant or  
carrier 
Ag  
deliv-
ery 
Mouse 
strain 
Challenge Immune responses Brain cyst 
load 
Survival Refer-
ences 
ROM4+GRA14 CaPNs Plas-
mid, 
i.m 
BALB/c 1 × 103 
tachyzoites, 
RH strain, i.p 
Induced a strong IgG antibody re-
sponse (P < 0.05) 
 
Induced mixed Th1/Th2 immune 
responses with predominance of 
IgG2a over IgG1 
 
↑ splenocyte proliferation (P < 
0.05) 
 
↑ IFN-γ (P < 0.05) 
 
Similar levels of  IL-4 between im-
munized mice and control groups 
(P > 0.05) 
Not re-
ported 
Increased survival time 
(P < 0.05) 
 
pcROM4 + pcGRA14: 
death within 14 days (P 
< 0.05) 
 
pcROM4- 
CaPNs + pcGRA14-
CaPNs: death within 15 
days (P < 0.05) 
 
Control mice died 
within 6 days 
Rahimi et 
al., 2017 
ROM4 
DNA prime/pep-
tide boost 
- i.m BALB/c Acute: 1 × 104 
tachyzoites, 
RH strain, i.p 
 
Chronic: 20 tis-
sue cysts PRU 
strain, orally 
Induced a strong IgG antibody 
 response (P < 0.05) 
 
The predominance of IgG2a over 
IgG1 
 
↑ IFN-γ (778.2 ± 93.2 pg/ml, P < 
0.05), IL-2 (343.2 ± 22.4 pg/ml, P 
< 0.05), IL-12(p70) (247.1 ± 48.8 
pg/ml, P < 0.05) 
 
Similar levels of  IL-4 and IL-10 
between immunized mice and 
control groups (P > 0.05) 
Reduced 
(P < 0.05) 
Prolonged survival time 
(18 days compared 
with 6 days in control, P 
< 0.05) 
Han et 
al., 2017 
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this problem, usually require some additional 
components to elicit the immune response. 
Hence, the use of some adjuvants and also re-
peated boost immunizations are suggested to 
elevate the efficiency of subunit vaccines 
(Hansson et al., 2000; Kardani et al., 2016; 
Lee and Nguyen, 2015). Subunit vaccines 
mainly elicit a humoral immune response, 
while recombinant live vector vaccines and 
DNA vaccines predominantly induce the cel-
lular immunity (Kardani et al., 2016; 
Nascimento and Leite, 2012). One way to 
overcome this shortage is prime-boost strat-
egy which is a perfect technique to improve 
the efficiency of vaccination (Kardani et al., 
2016). In fact, the prime-boost strategy gener-
ates a more powerful immune response and 
elicit both humoral and cellular immune re-
sponses (Han et al., 2017; Li and Petrovsky, 
2016). The mechanism of prime-boost meth-
ods is as follows: the initial immunization 
primes the immune response and following 
immunizations motivate extra expansion of 
antigens (Kardani et al., 2016; Li and 
Petrovsky, 2016). One key issue in prime-
boost immunization is the order of vaccina-
tion process, e.g. sequence of using DNA as 
the prime and protein as the boost, the other 
important factor is the interval between using 
prime and boost in vaccination procedure, 
considering these aspects of prime-boosting 
immunization lead to strong immune re-
sponses (Foroutan et al., 2018b; Kardani et 
al., 2016). 
The prime-boost method consists of two 
types: homologous and heterologous prime-
boost regimens. Homologous prime-boost 
regimen covers the same formulation used in 
both prime and boost regimens, while heter-
ologous prime-boost regimens involve differ-
ent formulations (Kardani et al., 2016; Li and 
Petrovsky, 2016). Based on several studies, 
heterologous prime-boost immunizations 
have proven to be appropriate ways for im-
munization against different infections 
(Kardani et al., 2016; Li and Petrovsky, 
2016). Since, heterologous prime-boost regi-
mens strongly induce both humoral and cellu-
lar immune responses and elicit a robust im-
mune response, it is more efficient and more 
potent than homologous prime-boost 
(Kardani et al., 2016). Boosting a primary re-
sponse with a heterologous vector leads to 4 
to 10-fold higher responses in comparison 
with homologous prime-boost method 
(Kardani et al., 2016). Heterologous prime-
boost strategies principally use a DNA or a vi-
ral vector, particularly adenovirus for priming 
and a protein for boosting (Li and Petrovsky, 
2016), using various vectors leads to im-
proved levels of CD4+ and CD8+ T-cells in 
contrast to homologous boosting (Dunachie 
and Hill, 2003). 
In this case, Han and colleagues (2017) 
used DNA-priming and polypeptide-boosting 
regimen based on ROM4 (pROM4 prime/ 
ROM4 peptide boost) in BALB/c mice in or-
der to investigate the levels of IgG, IgG2a, 
IgG1, and the main cytokines in different 
mouse groups. The results indicate that 
BALB/c mice vaccinated with DNA/peptide 
had the most levels of the IgG, IgG2a, IgG1, 
IL-2, IL-12 and IFN-γ. Moreover, the mice 
vaccinated with DNA/peptide showed the 
maximum survival time and the lowest brain 
cyst load in comparison with the control 
group. About 1×104 tachyzoites of T. gondii 
RH strain were intraperitoneally injected to 
all mice. All mice in the negative control 
groups died on day 6, but those groups which 
received prime-boost regimen, survived until 
day 18. The authors concluded that ROM4 in-
duces the highest level of immune response 
than other regimens, which could be consid-
ered as a promising approach to elevate the 
efficacy of vaccination against acute and 
chronic T. gondii infection (Han et al., 2017). 
 
CONCLUDING REMARKS 
T. gondii infects several intermediate 
hosts such as rodents, birds, marine mam-
mals, domestic/wild mammals, humans, etc. 
For example, approximately one third of the 
total individuals around the globe have anti-
T. gondii antibodies in their sera. In the two 
past decades, an increasing number of papers 
have been published using different vaccine 
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types and various strategies to assess the im-
munogenicity of T. gondii antigens. However, 
these attempts failed to introduce an effective 
vaccine against T. gondii infection, but prom-
ising achievements were obtained by re-
searchers. The use of DNA vaccines encoding 
ROM1, ROM4, and ROM5 alone or in com-
bination with other antigens elicited the im-
mune responses, prolonged the survival 
time/rate and reduced the brain cysts load 
among vaccinated mice. In addition, the use 
of prime-boost regimen by recruiting ROM4 
increased the survival duration up to 18 days 
post challenge. Nevertheless, these reports 
failed to show complete protection in immun-
ized mice. It should be noted that ROM4 is 
expressed in the majority stages of T. gondii 
life cycle (primarily in tachyzoites, at lower 
levels in bradyzoites, and weakly in sporozo-
ites). Also, it is involved in several vital func-
tions of Toxoplasma. So that, the suppression 
of ROM4 leads to the following defects: par-
tially impairment in lytic growth, reduction of 
the frequency of moving junction formation, 
and disruption of normal gliding. In regard to 
the above mentioned points, the vast use of 
ROM4 by researchers is justifiable. However, 
there are no published articles about ROM2, 
ROM3, and ROM6 in terms of vaccination 
against T. gondii infection. On the other 
hands, unfortunately, there were no reports re-
garding the use of vaccines based on live-at-
tenuated vectors and multi-epitope vaccines 
for ROM-based antigens, which require more 
consideration in future investigations by sci-
entists. Moreover, co-delivery of genetic 
and/or non-genetic adjuvants surely would in-
fluence the outcomes in vaccinated groups. 
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